Parsortix, which harvests tiny circulating tumour cells, has been used to assess better treatment options in a range of cancers including breast and prostate.
In work carried out by the University Medical Centre Hamburg-Eppendorf assessing the spread of non-small cell lung cancer (NSCLC), the team there concluded activated leukocyte cell adhesion molecule (ALCAM) is key to brain metastasis.
In fact, the study showed ALCAM protein expression on circulating tumour cells, harvested by Parsortix, matched the protein expression in brain tissue biopsies.
This suggests the ANGLE device may be able to aid the assessment of lung cancer sufferers at risk of a spread to the brain.
Currently, the only way to assess whether the disease has developed in this way is to carry out a “highly invasive” tissue biopsy.
Breast and prostate cancers
It is also thought the approach pioneered in Hamburg will work in assessing the spread of breast and prostate cancers.
“This is tremendous work by the world-class Hamburg-Eppendorf cancer centre. The potential of staining circulating tumour cells harvested by Parsortix for ALCAM protein expression provides an excellent opportunity for ANGLE where Parsortix has unique competitive advantages,” said Andrew Newland, ANGLE’s chief executive.
“Brain metastases cannot be accessed for biopsy without highly invasive procedures and a liquid biopsy alternative would be of great benefit to patients to inform treatment.”
Body of evidence
“This represents the 30th peer-reviewed independent research using Parsortix,” said Mark Brewer, analyst at broker finnCap.
“The near-term focus remains the potential for FDA [Food & Drug Administration] clearance of Parsortix in late 2020, which will be a watershed moment for further clinical applications to be developed.”
The company hopes to receive the regulatory green light for the device from the US regulator by the third quarter of this year.
The ANGLE share price rose 5% to 67p. finnCap reckons the stock is worth 135p.
—adds broker comment and share price—